Policy for in-vivo Experimental Neoplasia:
1. All transplantable tumors should be assayed
for contamination with adventitious murine viruses such as (but not limited
to) CAR bacillus, H-1 virus, KRV (Kilham Rat Virus), LCM (Lymphocytic Choriomeningitis
virus), Mycoplasma pulmonis, parvovirus, PVM (Pneumonia Virus of
Mice), RCV/SDAV (Rat Corona Virus/Sialodacryoadenitis Virus), Reovirus and
2. Tumor implantation sites should be chosen
to minimize damage to adjacent normal structures. Sites involving the
special senses should be avoided, and intramuscular implantation should be
avoided as distention of muscle is considered to be painful to the animal. Subcutaneous
or intradermal implantation in the flank is considered least painful and is
the preferred site.
3. Tumors should not exceed 5% of the body
weight of the animal, and animals should be euthanized when tumors exceed
this threshold. In the case of a mouse weighing 25g this would represent
a single subcutaneous nodule of approximately .75 cm in diameter.
4. Tumors should not interfere with normal
bodily functions (i.e., ambulation, eating, drinking, defecating, and/or urinating). Some
tumors or the anti-tumor therapy may cause the animal to lose condition. In
these situations, animals that lose greater than 20% of their body weight
or fail to attain weight 20% lower than untreated controls should be euthanized. If
the tumor interferes with normal bodily functions and the animal appears to
be in distress, the animal should be euthanazed regardless of the size of
the tumor or the weight of the animal.
5. Some tumors will ulcerate; if ulceration
occurs, the animal must be intensively monitored for any untoward signs of
distress (i.e.: excess bleeding) and be humanely euthanized at that time.
6. Animals should be examined at least daily
after tumor implantation.
7. End points of experimental neoplasia should
be determined and specified in the experimental protocol. In addition,
guidelines for early removal criteria should be established within the protocol.